Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Besse

Showing results (101-110 of 139) with videos related to

Pageof 14
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug AdministrationG Mountzios, J Remon, S Novello, et al.
Respiratory Medicine and Research|June 22, 2020
Proposals for managing patients with thoracic malignancies during COVID-19 pandemicN Girard, L Greillier, G Zalcman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2021
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>A-M C Dingemans, M Früh, A Ardizzoni, et al.
Lung Cancer (Amsterdam, Netherlands)|June 3, 2020
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer expertsM Früh, C M Panje, M Reck, et al.
Scientific Reports|May 18, 2022
Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platformM Morfouace, S Novello, A Stevovic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2017
A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroupsC R Lindsay, V Faugeroux, S Michiels, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2019
Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patientsM Charrier, L Mezquita, B Lueza, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2017
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNAJ Remon, C Caramella, C Jovelet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohortJ Mazières, F Barlesi, T Filleron, et al.
Diagnostic and Interventional Imaging|October 6, 2020
Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung diseaseL Tselikas, L Garzelli, O Mercier, et al.
Pageof 14

Showing results (101-110 of 139) with videos related to

Sort By:
Pageof 14
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug AdministrationG Mountzios, J Remon, S Novello, et al.
Respiratory Medicine and Research|June 22, 2020
Proposals for managing patients with thoracic malignancies during COVID-19 pandemicN Girard, L Greillier, G Zalcman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2021
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>A-M C Dingemans, M Früh, A Ardizzoni, et al.
Lung Cancer (Amsterdam, Netherlands)|June 3, 2020
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer expertsM Früh, C M Panje, M Reck, et al.
Scientific Reports|May 18, 2022
Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platformM Morfouace, S Novello, A Stevovic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2017
A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroupsC R Lindsay, V Faugeroux, S Michiels, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2019
Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patientsM Charrier, L Mezquita, B Lueza, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2017
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNAJ Remon, C Caramella, C Jovelet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohortJ Mazières, F Barlesi, T Filleron, et al.
Diagnostic and Interventional Imaging|October 6, 2020
Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung diseaseL Tselikas, L Garzelli, O Mercier, et al.
Pageof 14